跳至主要内容
临床试验/EUCTR2005-002134-35-AT
EUCTR2005-002134-35-AT进行中(未招募)不适用

EXTENSION STUDY TO INVESTIGATE THE EFFICACY, SAFETY AND TOLERABILITY OF ESLICARBAZEPINE ACETATE (BIA 2-093) IN THE RECURRENCE PREVENTION OF BIPOLAR I DISORDER

Bial - Portela & Cª, S.A.0 个研究点目标入组 160 人开始时间: 2005年8月23日最近更新:
适应症

试验速览

阶段
不适用
状态
进行中(未招募)
发起方
入组人数
160

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • informed consent form signed; completed the 3-week treatment period in Protocol SCO/BIA-2093-203 or Protocol PRA/BIA-2093-204 and shown response to treatment [i.e., = 50% improvement in the Young Mania Rating Scale (YMRS) total score or an YMRS total score < 12]; in case of woman of childbearing potential, patient presents a serum pregnancy test consistent with a non-gravid state and will use double-barrier contraception throughout the study.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range

排除标准

  • relevant ECG or laboratory abnormalities; any uncontrolled clinically relevant disorder; not ensured capability to comply with the study protocol.

研究者

发起方
Bial - Portela & Cª, S.A.

相似试验

进行中(未招募)
不适用
EXTENSION STUDY TO INVESTIGATE THE EFFICACY, SAFETY AND TOLERABILITY OF ESLICARBAZEPINE ACETATE (BIA 2-093) IN THE RECURRENCE PREVENTION OF BIPOLAR I DISORDER - NA
EUCTR2005-002134-35-CZBIAL - Portela & Cª, SA160
进行中(未招募)
不适用
EXTENSION STUDY TO INVESTIGATE THE EFFICACY, SAFETY AND TOLERABILITY OF ESLICARBAZEPINE ACETATE (BIA 2-093) IN THE RECURRENCE PREVENTION OF BIPOLAR I DISORDER
EUCTR2005-002134-35-PTBial - Portela & Cª, S.A.160
进行中(未招募)
1 期
EXTENSION STUDY TO INVESTIGATE THE EFFICACY, SAFETY AND TOLERABILITY OF ESLICARBAZEPINE ACETATE (BIA 2-093) IN THE RECURRENCE PREVENTION OF BIPOLAR I DISORDER - NAPatients with acute manic episode fulfilling DSM-IV criteria for Bipolar I Disorder (i.e., 296.0, 296.4 or 296.6)
EUCTR2005-002134-35-SKBIAL - Portela & Cª, SA160
进行中(未招募)
1 期
EXTENSION STUDY TO INVESTIGATE THE EFFICACY, SAFETY AND TOLERABILITY OF ESLICARBAZEPINE ACETATE (BIA 2-093) IN THE RECURRENCE PREVENTION OF BIPOLAR I DISORDERPatients with acute manic episode fulfilling DSM-IV criteria for Bipolar I Disorder (i.e., 296.0, 296.4 or 296.6). --> recurrence prevention of Bipolar I Disorder
EUCTR2005-002134-35-DEBIAL - Portela & Cª, SA160
进行中(未招募)
1 期
EXTENSION STUDY TO INVESTIGATE THE EFFICACY, SAFETY AND TOLERABILITY OF ESLICARBAZEPINE ACETATE (BIA 2-093) IN THE RECURRENCE PREVENTION OF BIPOLAR I DISORDEREnsayo de extensión para estudiar la eficacia, seguridad y tolerabilidad de Acetato de Eslicarbazepina (BIA- 2-093) en la prevención de la recurrencia del trastorno bipolar I
EUCTR2005-002134-35-ESBIAL - Portela & Ca, S.A.160